Dilated cardiomyopathy 1A
MONDO:0007269Familial dilated cardiomyopathy with conduction defect due to LMNA mutation is a rare familial dilated cardiomyopathy characterized by left ventricular enlargement and/or reduced systolic function preceded or accompanied by significant conduction system disease and/or arrhythmias including bradyarrhythmias, supraventricular or ventricular arrhythmias. Disease onset is usually in early to mid-adulthood. Sudden cardiac death may occur and may be the presenting symptom. In some cases, it is associated with skeletal myopathy and elevated serum creatine kinase.
Also known as: CDCD1, LMNA familial isolated dilated cardiomyopathy, cardiomyopathy dilated with conduction defect type 1, cardiomyopathy, dilated, type 1A, dilated cardiomyopathy 1A, dilated cardiomyopathy type 1A, familial dilated cardiomyopathy with conduction defect due to LMNA mutation, familial isolated dilated cardiomyopathy caused by mutation in LMNA
10 clinical trials for this condition and its sub-types, 2 tagged with Dilated cardiomyopathy 1A itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Gene therapy trial aims to fix heart muscle in rare genetic disease
Disease control Recruiting nowThis early-stage trial tests a single dose of a gene therapy called NVC-001 in 21 adults with a genetic form of dilated cardiomyopathy (LMNA mutation). The therapy uses a harmless virus to deliver a modified gene into heart cells, aiming to protect the heart muscle. The main goal…
Phase 1/2 • Sponsor: Nuevocor Pte. Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Scientists hunt for 'Modifier Genes' that could explain why some LMNA patients fare better than others
Knowledge-focused Recruiting nowThis study aims to identify genetic factors that affect how severe muscle and heart problems become in people with LMNA gene mutations. Researchers will collect skin and muscle samples from 40 participants and use advanced DNA and RNA analysis to look for protective or aggravatin…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC